This pilot study evaluated a multi-modal longevity protocol combining lifestyle optimisation, nutritional supplementation, and autologous cell-free conditioned media derived from peripheral blood-derived pro-regenerative cells (APRC-CM). Fourteen healthy adult participants completed a 17-week programme including baseline and post-intervention biomarker assessments. The primary objective was to characterise changes in biological age using DNA methylation-based epigenetic clocks, PhenoAge and other physiological and biochemical markers.

This exploratory study investigated the biological effects of a structured, multi-modal longevity programme that included lifestyle optimisation (nutrition, exercise, sleep routines), nutritional supplementation, and autologous cell-free conditioned media (APRC-CM). APRC-CM was prepared individually for each participant from peripheral blood-derived pro-regenerative cells cultured ex vivo to produce a pro-regenerative secretome containing soluble factors and extracellular vesicles.

Participants underwent biomarker assessments at baseline and at week 17. Outcomes included measurements of epigenetic biological age, phenotypic age, inflammatory markers, metabolic markers, and other laboratory and physiological variables. The study was conducted in healthy adults and designed as a minimal-risk physiological investigation.

Inclusion Criteria:

• Age 45 years or older
• Generally good overall health as assessed by the study team
• Able and willing to provide written informed consent
• Willing to participate in all components of the study protocol, including lifestyle optimisation, nutritional supplementation, blood collection, and scheduled follow-up visits
• Able to comply with study procedures for the duration of the intervention and assessments

Exclusion Criteria:

• Presence of a major medical condition that, in the opinion of the investigators, could affect participation or safety
• Any condition requiring hospitalization or emergency medical intervention within the past 12 months
• Receipt of anti-aging or longevity treatments within the past six months (e.g., intravenous therapies, regenerative or cellular treatments, structured age-reversal programmes)
• Active infectious disease at enrolment
• Pregnancy or breastfeeding
• Use of systemic immunomodulatory, cytotoxic, or investigational treatments in the prior 3 months
• Any condition or circumstance that, in the judgement of the investigators, may interfere with study participation or data integrity

Individual participant data will not be shared because the dataset includes biological, clinical, and demographic information that may be potentially identifiable, and no data-sharing agreements or infrastructure were established for this pilot study.